Evaluation of Safety, PK, and Preliminary Effects on Scar Formation of Multiple Intradermal Administrations of RXI-109

A Phase 1 Single Center, Randomized, Double-Blind, Ascending, Multi-Dose, Within-Subject Controlled Study of RXI-109 for the Treatment of Incision Scars Made in the Abdominal Skin of Healthy Subjects

The purpose of this trial is to evaluate the safety and tolerability of multiple (3) intradermal doses of RXI-109 at small surgical incisions in the abdominal skin of healthy volunteers. The effect of RXI-109 versus placebo on scarring at these incision sites will be evaluated visually, histologically, and by biomarker analysis.

Inclusion Criteria:

• Males and females, 21-50 years of age
• General good health; if female not pregnant or lactating
• Phototype 3 and above based on the Fitzpatrick scale.

Exclusion Criteria:

• Pregnant or lactating
• Use of tobacco or nicotine-containing products within 1 month prior to enrollment and while on study
• Type 1 or 2 diabetes mellitus
• A history or presence of any medical condition or therapy that would make the subject an unsafe candidate in the opinion of the investigator